Treatment of splenic marginal zone lymphoma with rituximab monotherapy: Progress report and comparison with splenectomy

Oncologist

Volumn 18, Issue 2, 2013, Pages 190-197

  Kalpadakis, Christina ^a   Pangalis, Gerassimos A ^a,b   Angelopoulou, Maria K ^a   Sachanas, Sotirios ^b   Kontopidou, Flora N ^a   Yiakoumis, Xanthi ^b   Kokoris, Stella I ^a   Dimitriadou, Evagelia M ^b   Dimopoulou, Maria N ^a   Moschogiannis, Maria ^b   Korkolopoulou, Penelope ^c   Kyrtsonis, Marie Christine ^a   Siakantaris, Marina P ^a   Papadaki, Theodora ^d   Tsaftaridis, Panayiotis ^a   Plata, Eleni ^a   Papadaki, Helen E ^a   Vassilakopoulos, Theodoros P ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c ATHENS MEDICAL CENTER   (Greece)

^d EVANGELISMOS HOSPITAL   (Greece)

Author keywords

Rituximab; Splenectomy; Splenic marginal zone lymphoma

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; LACTATE DEHYDROGENASE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; DEATH; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HYPOTENSION; IMMUNOPHENOTYPING; LYMPHADENOPATHY; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RELAPSE; RETROSPECTIVE STUDY; SPLENECTOMY; SPLENIC MARGINAL ZONE LYMPHOMA; SPLENOMEGALY; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA, B-CELL, MARGINAL ZONE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SPLENECTOMY; SPLENIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84874381576     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0251     Document Type: Article

References (41)

1. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes. NonHodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16:2780-2795.
2. Isaacson PG, Piris MA, Berger F et al. Splenic Bcell marginal zone lymphoma. In: World Health Organization. Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC, 2008:185-187.
3. Matutes E, Oscier D, Montalban C et al. Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia 2008; 22:487-495.
4. Matutes E, Morilla R, Owusu-Ankomach K et al. The immunophenotype of splenic lymphoma with villous lymphocytes and its relevance to the differential diagnosis with other B-cell disorders. Blood 1994; 83:1558-1562.
5. Franco V, Florena AM, Iannitto E. Splenic marginal zone lymphoma. Blood 2003; 101:2464-2472.
6. Oscier D, Owen R, Johnson S. Splenic marginal zone lymphoma. Blood Rev 2005; 19:39-51.
7. Berger F, Felman P, Thieblemont C et al. NonMALT marginal zone B-cell lymphomas: A description of clinical presentation and outcome in 124 patients. Blood 2000; 95:1950-1956.
8. Thieblemont C, Felman P, Callet-Bauchu E et al. Splenic marginal-zone lymphoma: A distinct clinical and pathological entity. Lancet Oncol 2003; 4:95-103.
9. Chacón JI, Mollejo M, Muñoz E et al. Splenic marginal zone lymphoma: Clinical characteristics and prognostic factors in a series of 60 patients. Blood 2002; 100:1648-1654.
10. Thieblemont C, Felman P, Berger F et al. Treatment of splenic marginal zone B-cell lymphoma: An analysis of 81 patients. Clin Lymphoma 2002; 3:41-47.
11. Troussard X, Valensi F, Duchayne E et al. Spleniclymphomawithvillouslymphocytes:Clinical presentation, biology and prognostic factors in a series of 100 patients. Groupe Fraņis d'Hématologie Cellulaire (GFHC). Br J Haematol 1996; 93:731-736.
12. Parry-Jones N, Matutes E, Gruszca-Westwood AM et al. Prognostic features of splenic lymphoma with villous lymphocytes: A report on 129 patients. Br J Haematol 2003; 120:759-764.
13. Mulligan SP, Matutes E, Dearden C et al. Splenic lymphoma with villous lymphocytes: Natural history and response to therapy in 50 cases. Br J Haematol 1991; 78:206-209.
14. Arcaini L, Lazzarino M, Colombo N et al. Splenic marginal zone lymphoma: A prognostic model for clinical use. Blood 2006; 107:4643-4649.
15. Algara P, Mateo MS, Sanchez-Beato M et al. Analysis of the IgV(H) somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course. Blood 2002; 99:1299-1304.
16. Gruszka-Westwood AM, Hamoudi RA, Matutes E et al. p53 abnormalities in splenic lymphoma with villous lymphocytes. Blood. 2001; 97:3552-3558.
17. Camacho FI, Mollejo M, Mateo MS et al. Progression to large B-cell lymphoma in splenic marginal zone lymphoma: A description of a series of 12 cases. Am J Surg Pathol 2001; 25:1268-1276.
18. Ruiz-Ballesteros E, Mollejo M, Rodriguez A et al. Splenic marginal zone lymphoma: Proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis. Blood 2005; 106:1831-1838.
19. Salido M, Baró C, Oscier D et al. Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: A multicenter study of the Splenic B-Cell Lymphoma Group. Blood 2010; 116:1479-1488.
20. Matutes E. Splenic marginal zone lymphoma with and without villous lymphocytes. Curr Treat Options Oncol 2007; 8:109-116.
21. Iannitto E, Ambrosetti A, Ammatuna E et al. Splenic marginal zone lymphoma with or without villous lymphocytes. Hematologic findings and outcomes in a series of 57 patients. Cancer 2004; 101: 2050-2057.
22. Lefrère F, Hermine O, Belanger C et al. Fludarabine: An effective treatment in patients with splenic lymphoma with villous lymphocytes. Leukemia 2000; 14:573-575.
23. Bennett M, Sharma K, Yegena S et al. Rituximab monotherapy for splenic marginal zone lymphoma. Haematologica 2005; 90:856-858.
24. Tsimberidou AM, Catovsky D, Schlette E et al. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer 2006; 107:125-135.
25. Kalpadakis C, Pangalis GA, Dimopoulou MN et al. Rituximab monotherapy is highly effective in splenic marginal zone lymphoma. Hematol Oncol 2007; 25:127-131.
26. Kalpadakis C, Pangalis GA, Vassilakopoulos TP et al. Rituximab monotherapy is the treatment of choice for splenic marginal zone lymphoma (SMZL). Ann Oncol 2008; 19:Abstract #367.
27. Shipp MA. Prognostic factors in aggressive non-Hodgkin's lymphoma: Who has "high-risk" disease? Blood 1994; 83:1165-1173.
28. Kalpadakis C, Pangalis GA, Dimitriadou E et al. Mutation analysis of IgVH genes in splenic marginal zone lymphomas: Correlation with clinical characteristics and outcome. Anticancer Res 2009; 29: 1811-1816.
29. Catovsky D, Matutes E. Splenic lymphoma with circulating villous lymphocytes/splenic marginal-zone lymphoma. Semin Hematol 1999; 36: 148-154.
30. Bennett M, Schechter GP. Treatment of splenic marginal zone lymphoma: Splenectomy versus rituximab. Semin Hematol 2010; 47:143-147.
31. Fabbri A, Gozzetti A, Lazzi S et al. Activity of rituximab monotherapy in refractory splenic marginal zone lymphoma complicated with autoimmune hemolytic anemia. Clin Lymphoma Myeloma 2006; 6:496-499.
32. Paydas S, Yavuz S, Disel U et al. Successful rituximab therapy for hemolytic anemia associated with relapsed splenic marginal zone lymphoma with leukemic phase. Leuk Lymphoma 2003; 44: 2165-2166.
33. Kluin-Nelemans HC, Hoster E, Hermine O et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012; 367:520-531.
34. Sachanas S, Pangalis GA, Vassilakopoulos TP et al. Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: A highly effective regimen. Leuk Lymphoma 2011; 52:387-393.
35. Salles G, Seymour JF, Offner F et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial. Lancet 2011; 377: 42-51.
36. Franco V, Florena AM, Stella M et al. Splenectomy influences marrow infiltration in patients with splenic marginal zone cell lymphoma with or without villous lymphocytes. Cancer 2001; 91:294-301.
37. Bolam S, Orchard J, Oscier D. Fludarabine is effective in the treatment of splenic lymphoma with villous lymphocytes. Br J Haematol 1997; 99:158-161.
38. Iannitto E, Minardi V, Calvaruso G et al. Deoxycoformycin (pentostatin) in the treatment of splenic marginal zone lymphoma (SMZL) with or without villous lymphocytes. Eur J Haematol 2005; 75:130-135.
39. Lefrère F, Hermine O, Frano̧is S et al. Lack of efficacy of 2-chlorodeoxyadenoside in the treatment of splenic lymphoma with villous lymphocytes. Leuk Lymphoma 2000; 40:113-117.
40. Riccioni R, Caracciolo F, Galimberti S et al. Low dose 2-CdA schedule activity in splenic marginal zone lymphomas. Hematol Oncol 2003; 21:163-168.
41. Cervetti G, Galimberti S, Sordi E et al. Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL). Ann Oncol 2010; 21:851-854.